BRAF and metastatic melanoma: Finally, atezolizumab, in combination with mitogen-activated extracellular kinase (MEK) inhibitor cobimetinib and B-Raf enzyme inhibitor called vemurafenib, has been approved for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma [60].